RIVA-CANDESARTAN TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
20-10-2016
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
CANDESARTAN CILEXETIL
Tilgjengelig fra:
LABORATOIRE RIVA INC.
ATC-kode:
C09CA06
INN (International Name):
CANDESARTAN
Dosering :
4MG
Legemiddelform:
TABLET
Sammensetning:
CANDESARTAN CILEXETIL 4MG
Administreringsrute:
ORAL
Enheter i pakken:
30/100
Resept typen:
Prescription
Terapeutisk område:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0135220001; AHFS:
Autorisasjon status:
CANCELLED POST MARKET
Autorisasjon dato:
2019-04-01
Preparatomtale
_RIVA-CANDESARTAN Product Monograph_
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
RIVA-CANDESARTAN
Candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Québec
J7C 3V4
www.labriva.com
DATE OF REVISION
:
October 17, 2016
Submission Control No: 198061
_RIVA-CANDESARTAN Product Monograph_
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
............................................................................................
Les hele dokumentet
